Data & Analytics: New Frontiers for Big Data
Journal Ad Review: Paper Chase
Therapeutic Focus 2014: Metabolic
Specialty Pharma: Coverage at the Crossroads
MAHF 2014: Honoring Our Heroes
MM&M Awards: How to Win
Private View: Telling good brand stories
Read the complete 2014 MM&M Digital Guide digital edition
A rival's late-stage trial results suggest the pain med may have a short market life. The key: an FDA division head's documented willingness to overturn the approval should another pain option surface.
Analysts indicate the earlier-than-expected patent loss will not be a significant upset to Pfizer's present. The drugmaker plans to appeal the decision.
A report of over 270,000 US medical sites signals that EHR adoption is no longer a luxury reserved for hospitals and health systems.
The FDA's bad-ad unit took a drugmaker to task for what it calls a misleading Facebook page. History shows the social media surveillance should take no one by surprise.
Why I left SXSW this past week feeling like I just might live forever
PhRMA and the National Minority Quality Forum's "I'm In" campaign seeks to tackle clinical trial diversity (or the lack thereof).
Plans for a "new regulatory supergroup" are reported to have been in the works for some time.
The manufacturer of the so-called "Botox for eyelashes" found the majority of women it surveyed were worried about thinning fringe.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
The new MM&M e-book, "Oncology Marketing," is designed to serve as a companion for those in the business of communicating cancer products to all three stakeholders. It's packed with analysis, advice, insights and commentary to help navigate the terrain. Click here to access it.